Results 31 to 40 of about 2,816 (233)
Retrospective Evaluation of The Cases with Malignant Pheochromocytoma: A Single Center Experience
IIntroduction The aim of this study was to evaluate the clinicodemographic factors and features of tumors in patients with malignant pheochromocytoma.
Yasemin Aydoğan Ünsal +7 more
doaj +1 more source
Development of 177Lu-phytate Complex for Radiosynovectomy [PDF]
Objective(s): In this work a new possible agent for radiosynovectomy has been targeted for articular pain palliation. Materials and Methods: Lu-177 of 2.6-3 GBq/mg specific activity was obtained by irradiation of natural Lu2O3 sample with thermal neutron
Hassan Yousefnia +5 more
doaj
177Lu-iPSMA is a novel radioligand developed at ININ-Mexico with a high affinity for the PSMA protein heavily expressed in cancer cells of approximately 95% of patients with metastatic castration-resistant prostate cancer (mCRPC).
Myrna Luna-Gutiérrez +13 more
doaj +1 more source
Pembuatan dan Analisis Fisiko-kimia Radioisotop Skandium-47 (47sc) dari Bahan Sasaran Titanium Oksida Alam [PDF]
Radioisotop skandium-47 (47Sc) memiliki waktu paruh 3,35 hari, pemancar energi beta, Eβmax 0,441 MeV (68 %) dan 0,601 MeV (32 %), serta pemancar energi gamma, Eγ 159 keV (68 %). Radioisotop 47Sc dihasilkan oleh iradiasi neutron cepat dari target titanium
Mulyati, T. S. (Titin) +1 more
core +2 more sources
Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology [PDF]
Background: Recent advances in nanotechnology have ofered new hope for cancer detection, prevention, and treatment. Nanomedicine, a term for the application of nanotechnology in medical and health felds, uses nanoparticles for several applica‑ tions such
Al Qahtani M. +12 more
core +1 more source
Biodistribusi 177lutetium-(r)-nodaga-psma pada Ginjal dan Kandung Kemih Tikus Galur Wistar Jantan [PDF]
177Lutetium (Lu) –(R)-NODAGA-PSMA merupakan perkembangan terapi radionuklida yang dapat digunakan untuk terapi metastasized castration-resistant prostate cancer (mCRPC).
Hidayati, N. R. (Nur) +4 more
core +2 more sources
Introduction. The use of radiopharmaceuticals for targeted radionuclide therapy (TRT), the efficacy of which was established during clinical trials, is safe and effective for various pathological conditions, including cancer.
E. P. Pavlenko +2 more
doaj +1 more source
Studi Awal Estimasi Dosis Internal 177lu-dota Trastuzumab pada Manusia Berbasis Uji Biodistribusi pada Mencit [PDF]
STUDI AWAL ESTIMASI DOSIS INTERNAL 177Lu-DOTA TRASTUZUMAB PADA MANUSIA BERBASIS UJI BIODISTRIBUSI PADA MENCIT. Radiofarmaka baru untuk pengobatan penyakit kanker payudara tipe HER-2, 177Lu-DOTA Trastuzumab, telah berhasil diproduksi oleh Pusat Teknologi ...
Aguswarini, S. (Sri) +13 more
core +2 more sources
This review systematically highlights the latest achievements in mixed‐valence states relevant to hydrogen and oxygen evolution reactions, providing essential insights into future directions and methods for large‐scale practical implementation. This critical review is expected to provide an overview of recent advancements in diverse valence‐state metal
Jitendra N. Tiwari +4 more
wiley +1 more source
Recently, the first squaramide-(SA) containing FAP inhibitor-derived radiotracers were introduced. DATA5m.SA.FAPi and DOTA.SA.FAPi with their non-radioactive complexes showed high affinity and selectivity for FAP.
Euy Sung Moon +7 more
doaj +1 more source

